Semaglutide and liraglutide on TikTok: separating GLP-1 fact from hype

What did @maplemesenchyme actually say?

The creator reports losing 25 pounds over six weeks on what they call "victosa" (they mean Victoza, the brand name for liraglutide). They also say their blood pressure has normalized and they hope to eventually reduce their antihypertensive medications. They mention nausea lasting anywhere from "a minute or two" to about a day, significant fatigue they can't fully attribute to the drug, and a candid reflection on the psychological risks of scale-watching. They also recommend "semaglotide" (semaglutide) by name, though the hashtags reference Victoza (liraglutide), which is a different drug entirely.

One thing to flag immediately: the creator uses "Victoza" and "semaglutide" interchangeably throughout the video. These are not the same medication. Victoza contains liraglutide. Ozempic and Wegovy contain semaglutide. The confusion matters clinically and is worth addressing head-on.

Does the science back this up?

The weight loss figure of 25 pounds in six weeks is at the high end of what's documented, but not impossible. It is, however, likely to slow down significantly. The blood pressure improvement claim is genuinely well-supported by research.

On weight loss: the SCALE trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found liraglutide 3.0 mg produced an average 8.4% body weight reduction over 56 weeks. Early rapid loss, especially in higher-weight individuals, is documented but typically front-loaded. A 25-pound loss in six weeks is aggressive and may partly reflect water weight and reduced food volume, not just fat loss.

On blood pressure: this is one of the more consistent secondary findings across GLP-1 trials. The LEADER trial (Marso et al., 2016, NEJM) showed liraglutide significantly reduced cardiovascular events and was associated with modest but real reductions in systolic blood pressure. The creator's experience here is biologically plausible and consistent with the evidence.

What did they get wrong (or right)?

The creator conflates liraglutide (Victoza) and semaglutide (Ozempic/Wegovy) as if they're the same drug. They are both GLP-1 receptor agonists, but they have different molecular structures, different dosing schedules, and meaningfully different efficacy data. Semaglutide at higher doses (as in Wegovy) outperforms liraglutide for weight loss in head-to-head data (Rubino et al., 2022, NEJM). Recommending one while taking the other is a real mix-up that viewers could act on incorrectly.

What they got right: the nausea description, "usually just like 20 minutes," aligns well with how GLP-1 side effects typically present. Transient nausea is the most reported adverse event in liraglutide trials, peaking early and diminishing over time (Davies et al., 2015, Diabetes Care). Their acknowledgment of fatigue as a potential confounder (schedule change, earlier wake times) is also genuinely good epistemic hygiene. The psychological framing around scale dependency is thoughtful and clinically relevant, though it is personal reflection, not medical guidance.

What should you actually know?

Several things here are worth separating out clearly before anyone watches this and makes decisions.

• Victoza (liraglutide) is FDA-approved for type 2 diabetes, and Saxenda (a higher-dose liraglutide formulation) is approved for chronic weight management. They are not the same product at the same dose.
• Semaglutide (Ozempic for diabetes, Wegovy for weight loss) is a distinct drug with higher average weight loss outcomes in clinical trials. The SURMOUNT and STEP trials show semaglutide and tirzepatide outperforming liraglutide for weight endpoints.
• The blood pressure improvement the creator describes is real and documented, but it does not mean someone should reduce or stop antihypertensive medications without physician oversight. That decision requires monitoring and a clinical conversation.
• Rapid early weight loss on GLP-1 medications is common but tends to plateau. Expecting 25 pounds every six weeks is not realistic over a full treatment course.
• The creator's point about psychological readiness before starting a weight-loss medication is not just feel-good advice. Research on binge eating disorder and GLP-1 use suggests psychological screening matters (Giel et al., 2022, Obesity Reviews).

Bottom line

This video has genuine value in its honesty about side effects, its nuanced take on scale obsession, and its real-world blood pressure data. But the Victoza-versus-semaglutide confusion is a meaningful error that 25,000 viewers should not walk away with. If you are considering a GLP-1 medication, the drug name, formulation, and approved dose all matter. This is a case where the creator's personal experience is largely credible, but their pharmacology is sloppy enough to be corrected.